Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board […]
(NASDAQ:OCGN), Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA) Executed licensing agreement with Kwangdong Pharmaceutical for exclusive rights in South Korea
(NASDAQ:RXRX), Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells–the second neuro map designed to accelerate treatments for a wide range of neurological diseases With this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborations Approximately $785
(NASDAQ:FTRE), For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 million GAAP net loss of $(15.9) million Adjusted EBITDA of $50.7 million GAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectively Book-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 months Cost
(NYSE:MGA),(TSX:MG), NCIB authorizes the discretionary repurchase of up to 25,300,000 Magna Common Shares, representing approximately 10% of Magna's public float. NCIB takes effect on November 7, 2025, and terminates no later than November 6, 2026. AURORA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) — Magna International Inc. (TSX: MG; NYSE: MGA) announces today the Toronto Stock
(NYSE:PSN), Q3 2025 Financial Highlights Q3 revenue of $1.6 billion decreased 10% year-over-year and 14% on an organic basis Revenue growth of 14% excluding confidential contract; 9% on an organic basis Q3 net income of $64 million decreased $8 million year-over-year Q3 adjusted EBITDA decreased 5% to $158 million; adjusted EBITDA margin of 9.8% increased
Ocugen Provides Business Update with Third Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET GlobeNewswire November 05, 2025 Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 05, 2025 Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells–the second neuro map designed to accelerate treatments for a wide range of neurological diseases With this achievement, Recursion will have reached over $500
Fortrea Reports Third Quarter 2025 Results GlobeNewswire November 05, 2025 For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 million GAAP net loss of $(15.9) million Adjusted EBITDA of $50.7 million GAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectively Book-to-bill ratio of 1.13x, resulting
Magna Announces Renewal of Normal Course Issuer Bid GlobeNewswire November 05, 2025 NCIB authorizes the discretionary repurchase of up to 25,300,000 Magna Common Shares, representing approximately 10% of Magna's public float. NCIB takes effect on November 7, 2025, and terminates no later than November 6, 2026. AURORA, Ontario, Nov. 05, 2025 (GLOBE NEWSWIRE) — Magna